#ES­MO20: It’s not just Keytru­da any­more — Mer­ck spot­lights 3 top ear­ly-stage can­cer drugs

Any $12 bil­lion megablock­buster in the port­fo­lio tends to over­shad­ow every­thing else in the pipeline. Which is some­thing Mer­ck can tell you a lit­tle bit about.

Keytru­da not on­ly dom­i­nates the PD-(L)1 field, it looms over every­thing Mer­ck does, to the point some an­a­lysts won­der if Mer­ck is a one-trick pony.

There’s no short­age of Keytru­da da­ta on dis­play at ES­MO this week­end, but now the fo­cus is shift­ing to the fu­ture role of new drugs and com­bos in main­tain­ing that lead po­si­tion for years to come. And the phar­ma gi­ant has a spe­cial fo­cus for 3 ear­ly-stage ef­forts where Roger Perl­mut­ter’s on­col­o­gy team is plac­ing some big bets.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER